Brokerages Expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to Announce $0.12 Earnings Per Share

Share on StockTwits

Wall Street brokerages forecast that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will post earnings per share of $0.12 for the current quarter, according to Zacks. Three analysts have made estimates for Vanda Pharmaceuticals’ earnings. The highest EPS estimate is $0.20 and the lowest is $0.04. Vanda Pharmaceuticals posted earnings per share of $0.26 in the same quarter last year, which suggests a negative year-over-year growth rate of 53.8%. The company is scheduled to announce its next quarterly earnings results on Wednesday, February 12th.

On average, analysts expect that Vanda Pharmaceuticals will report full-year earnings of $2.16 per share for the current fiscal year, with EPS estimates ranging from $2.08 to $2.24. For the next financial year, analysts expect that the firm will report earnings of $0.98 per share, with EPS estimates ranging from $0.13 to $1.83. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $1.77. Vanda Pharmaceuticals had a net margin of 55.49% and a return on equity of 38.90%. The company had revenue of $59.49 million during the quarter, compared to analysts’ expectations of $58.33 million. During the same quarter in the prior year, the company posted $0.13 EPS. The business’s revenue was up 21.1% on a year-over-year basis.

Several brokerages recently commented on VNDA. ValuEngine lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, November 8th. Stifel Nicolaus reissued a “hold” rating and set a $17.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, November 7th. Citigroup downgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $19.00 target price on the stock. in a research note on Thursday, November 7th. BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 27th. Finally, Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 16th. Two equities research analysts have rated the stock with a sell rating and five have given a hold rating to the company’s stock. Vanda Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $19.00.

Shares of VNDA stock traded up $0.01 during trading hours on Wednesday, hitting $16.41. The company had a trading volume of 291,283 shares, compared to its average volume of 540,622. Vanda Pharmaceuticals has a 12 month low of $11.83 and a 12 month high of $31.30. The firm’s fifty day moving average is $16.55 and its 200 day moving average is $14.55. The firm has a market capitalization of $875.31 million, a price-to-earnings ratio of 34.19 and a beta of 0.35.

Several hedge funds and other institutional investors have recently made changes to their positions in VNDA. North Star Investment Management Corp. acquired a new position in shares of Vanda Pharmaceuticals during the third quarter worth approximately $66,000. Meeder Asset Management Inc. raised its position in Vanda Pharmaceuticals by 1,638.3% in the 3rd quarter. Meeder Asset Management Inc. now owns 5,215 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 4,915 shares during the last quarter. Pacer Advisors Inc. bought a new position in Vanda Pharmaceuticals in the 2nd quarter worth approximately $138,000. Clarus Wealth Advisors acquired a new position in Vanda Pharmaceuticals during the 3rd quarter worth $133,000. Finally, Zebra Capital Management LLC acquired a new position in Vanda Pharmaceuticals during the 2nd quarter worth $170,000. 99.29% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Featured Article: How to Invest in an Index Fund

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.